Expanded Access Summit (@Expanded_Access) header
Expanded Access Summit (@Expanded_Access) profile picture

Ax-S Pharma, producer of the annual global conference on integrating pre-approval access into clinical drug development.

Washington, DC
Joined April 2018
Photo by Expanded Access Summit (@Expanded_Access)Photo by Expanded Access Summit (@Expanded_Access)Photo by Expanded Access Summit (@Expanded_Access)Photo by Expanded Access Summit (@Expanded_Access)Photo by Expanded Access Summit (@Expanded_Access)Photo by Expanded Access Summit (@Expanded_Access)
Congressional Hearing on funding for #ExpandedAccess in #ALS taking place right now. We'll be fact checking the whole way. energycommerce.house.gov/com…
14
2
1
1
Replying to @maxwellsmith
In the U.S., people won't get vaxxed because they're told it's good for them or good for public health. They'll do it because it's required at every workplace, store, airport, or gathering. As you say, it's a choice, not a mandate.
Replying to @maxwellsmith
Liberty is not counterpositioned to safety in this matter. A true libertarian supports an organization's right to protect its workforce, customers, guests, and attendees by denying entry to unvaxxed people. The public health "mandate" concept is misleading and problematic.
1
Replying to @bsw5020 @US_FDA
Here's how EA helps research trials, as we presented at NEALS #ALS forums 2013-2016. #ExpandedAccess programs, if made visible in advance, assure research trial participants that they'll have option to continue w/ active drug upon completion of study. Recruitment AND Retention.
FDA's position and @DrWoodcockFDA position on #ExpandedAccess has been excellent. The OP may be referring to the oft-repeated motto "the surest way to bring a new treatment to the most people is through well-controlled clinical trials", which (falsely) implies conflict with EA.
Expanded Access Summit retweeted
Despite some criticism, business owners said the overwhelming majority of people applauded them for requiring vaccines upon entry. businessinsider.com/business…
44
74
18
286
Although, comparing to seatbelts in cars is vulnerable to a libertarian counterargument, because failing to buckle up only harms the decision-maker. In contrast, failing to get SARS-COV2 vax harms the rest of us by prolonging the pandemic & putting other individuals at high risk
Replying to @GovAbbott
We absolutely agree on this one!
Yes, our name reflects our dedication to access - to modern healthcare, to investigational treatment options, and to the learning that can be generated by integrating research into widespread care practice. Call us crazy, but we think access is the key to a lot of good things.
Interpret it how you want. Misrepresent it if you want. But our comments are clear, and they're consistent with the law and with FDA's flexibility around treatment access in diseases where flexibility is needed most.
Replying to @ProfRobHoward
Luckily the second is not a precondition for the first. Nevertheless we know the history, and there are many cases of EAP-generated datasets contributing substantially to the body of knowledge on the particular treatment and disease, perhaps more-so in cancer EAPs than AIDS.
Replying to @nadia_sethi
Ha! It took me a while too. Here is the trick: Don't pronounce all 7 syllables. Say: Neuro-De-GenRative. We should have provided this to the Committee members today!
More questions from Committee members about how to make #ClinicalTrials more inclusive. FDA missing a huge opportunity to educate lawmakers about #ExpandedAccess channel, which is the intended channel for humanitarian widening of eligibility for investigational treatment.
Research trials need to be diverse, but not broadly inclusive in terms of numbers of patients. The clinical research enterprise was not created to provide a treatment option for whole populations. That's what #ExpandedAccess is for.
1
Rep Sarbanes, re Section 610 of PDUFA 6, requiring examination of trial inclusion/exclusion criteria. Ax-S Pharma: We authored some of the key language in this law to make sure the focus remained on utilizing #ExpandedAccess to increase overall inclusivity.
We have a special channel called #ExpandedAccess to accommodate the massive range of patients in therapeutic area who are OUTSIDE the eligibility criteria of research trials. Bending the inclusion/exclusion of research trials will never be a meaningful solution for inclusiveness
2
Reg Griffith (VA) to Dr. Koroshetz (NIH), why are we so slow recruiting in #ALS trials? A: This disease area is actually pretty good in trial enrollment. Ax-S Comment: The problem isn't speed of enrolling research trials. It's about the 90% of pALS who are study-ineligible.
1
1
Castor: Guidance advises larger, secondary cohorts to explore differential response. How has industry responded to this?
Cavazzoni: It's a very special disease with particularly challenging factors in clinical development. Also much greater tolerance for risk in the patient community wrt benefit/risk tradeoff.
1
Rep Castor (FL) Why did FDA develop specific Guidance for ALS drug development?
1
Rep Burgess; is FDA utilizing data generated by the Federally funded ALS Registry? A: not prepared to answer